This section keeps you updated on any major developments throughout the course of the DECISION project. For PDFs of our own press releases please go to DOWNLOADS. To receive our project newsletter please subscribe here!
09 June 2021
Successful patient event on 9th June
27 representatives of national patient organisations from 10 European countries listened to talks about therapies for cirrhosis and ACLF, research needs and outlook for the future. A lot of interest was shown towards available and new therapies for decompensated cirrhosis and ACLF. The event was organised by ELPA (president Marko Korenjak) and chaired by Prof. Rajiv Jalan, scientific director of EFCLIF.
15 April 2021
DECISION Steering Committee Meeting
From 14th – 15th April, the DECISION Steering Committee met again fully virtual. 20 participants exchanged information about progress and results. Great achievement: all ACLARA samples, which are relevant for the work of DECISION, now reached the partner labs. Now the work on these samples can start and we cannot wait to see results.
02 March 2021
Pierre-Emmanuel Rautou is being interviewed by “Science et Vie”
In its March issue, the French journal for laymen on science “Science et Vie” interviewed DECISION coordinator Pierre-Emmanuel Rautou on the topic of multi-omics and the acceleration of biomedicine. By decoding the hidden information at the heart of our cells, multi-omics is revolutionising many areas of research. Click below to read further [Articles in French]:
25 November 2020
Successful virtual General Assembly Meeting
On 24-25 Nov 2020, 51 members of the DECISION consortium and 4 members of the Scientific and Ethical Advisory Board met online to discuss the progress made during the first 8 months and important next steps. Despite the COVID-19 pandemic, the project is largely on track and important first results have been delivered. Still we all cannot wait to meet in person next time to speed up the communication and international collaboration!
10 September 2020
Codes of conduct applicable and research integrity policy including publications in journals published
This document is an analysis of the current codes of good conduct published by each member of the DECISION project: Here, we discuss what is included in the DECISION partners’ code of conduct, any references to national or international guidelines, how easily accessible the relevant information is from the home page and the general usefulness of the document for the members of the institutions themselves and the public.
31 August 2020
Public engagement strategy to design DECISION along with the need of patients finalized
The goal of this policy is to provide a framework of public engagement in research in DECISION to align this project with the Responsible Research and Innovation (RRI) framework.
27 August 2020
Prof. Dr. Paolo Caraceni from UNIBO, Italy, explains the clinical trial of DECISION
In this video, Prof. Dr. Paolo Caraceni explains the clinical trial, the predictive and response tests, the project’s approach to best-possible patient stratification, and the expected beneficial outcome of DECISION.
28 July 2020
DECISION in less than 5 minutes: Prof. Pierre-Emmanuel Rautou explains the project in a brief video
Take a few minutes to listen to Prof. Pierre-Emmanuel Rautou, the scientific coordinator of DECISION, explain and show to you what the project is all about.
27 July 2020
First Patient Event on 31st Aug 2020!
SAVE THE DATE: We kindly invite you to the 1st DECISION and ELPA patient event. Our first patient event takes place ONLINE on Monday, August 31st, from 16-17h at Central European Standard Time (CEST). For questions and registration, please contact email@example.com.
27 July 2020
Important milestones achieved!
We are happy to report that all ethics approvals for data transfers have been received and 5348 samples from PREDICT and 400 from CANONIC have been sent for analysis to all participating labs. Congratulations WP1 team!
22 July 2020
ELPA president Marko Korenjak introduces DECISION from the perspective of cirrhosis patients in this video
In this 3-min-long video, Marko Korenjak, the current president of the European Liver Patients Association (ELPA), who is also a key project partner, introduces the scope and aims of the DECISION project.
19 July 2020
Interleukin-22 in acute-on-chronic liver failure (ACLF): A matter of ineffective levels, receptor dysregulation, or defective signalling?
Read the new article by Schwarzkopf et al. published in J Hep on 19 July 2020. This work addresses one of the new models used in DECISION: The authors analysed the effects of interleukin 22 (IL-22) in a mouse model of ACLF after chronic carbon tetrachloride (CCl4)-treatment (0.2 ml/kg, 2 times per week, i.p.) and acute precipitating injury using 2 injections of 0.4 ml/kg CCl4 in combination with an i.p. challenge with Klebsiella pneumonia, mimicking a bacterial infection.
13 July 2020
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology
To access the full article published on 13 July 2020 by Trebicka et al., click on the link below.
26 May 2020
The DECISION consortium elects members of the Impact Board
Today, we announce the members of the DECISION Impact Board (IB): Pierre-Emmanuel Rautou, Narsis Kiani, Marko Korenjak, Richard Moreau, Jonel Trebicka, Frank Uschner. The IB is chaired by Christian Trautwein.
13 May 2020
Project management talk on YouTube
DECISION’s project manager, Dr. Mary Gazea describes the most critical aspects of the project’s governance structure and the financial issues in a confidential YouTube video. All consortium members are highly encouraged to log into the intranet (KEYWAYS) and watch her presentation. It contains very valuable information to navigate successfully through the coming project years!
01 April 2020
DECISION kicks off!
Not an April Fool’s joke – Today, the 5.5-year long, pan-European research project begins. We are very excited to roll up our sleeves and start working!